Completed PHASE1 INTERVENTIONAL 7-arm NCT01904318

A Phase I Study of IDP-73152 Mesylate in Health Male Volunteer (PDF inhibitor)

A Dose Block-randomized, Doubled, Placebo-controlled, Single Dose, Dose-escalation Clinical Phase I Study to Evaluate the Safety, Pharmacokinetics and Food

Sponsor: IlDong Pharmaceutical Co Ltd

Conditions Healthy

Interventions IDP-73152 mesylate 1280 mg IDP-73152 mesylate 160 mg IDP-73152 mesylate 320 mg IDP-73152 mesylate 40 mg IDP-73152 mesylate 640 mg IDP-73152 mesylate 80 mg Placebo

Updated 6 times since 2017 Last updated: Feb 11, 2014 Started: Jul 31, 2013 Primary completion: Dec 31, 2013 Completion: Jan 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01904318, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by IlDong Pharmaceutical Co Ltd, it has been updated 6 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jul 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

IlDong Pharmaceutical Co Ltd

Data source: IlDong Pharmaceutical Co Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jongno-gu, South Korea